HDL and LDL cholesterol significantly influence β-cell function in type 2 diabetes mellitus

Current Opinion in Lipidology

Volumn 21, Issue 3, 2010, Pages 178-185

  Kruit, Janine K ^a   Brunham, Liam R ^a   Verchere, C Bruce ^b   Hayden, Michael R ^a  

^a Centre for Molecular Medicine and Therapeutics   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

cells; ABCA1; HDL; Type 2 diabetes mellitus

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; ARYLDIALKYLPHOSPHATASE 1; GLUCOSE TRANSPORTER 2; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; SERUM AMYLOID A; TOLL LIKE RECEPTOR;

APOPTOSIS; B LYMPHOCYTE; CELL SURVIVAL; CHOLESTEROL TRANSPORT; HUMAN; HYPERGLYCEMIA; IN VITRO STUDY; INFLAMMATION; INSULIN RELEASE; LOSS OF FUNCTION MUTATION; LYMPHOCYTE FUNCTION; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; REVIEW;

ANIMALS; CELL SURVIVAL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION; INSULIN-SECRETING CELLS;

EID: 77952401289     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328339387b     Document Type: Review

References (65)

1. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 1967; 46:1954-1962.
2. Kahn SE, Zraika S, Utzschneider KM, Hull RL. The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality. Diabetologia 2009; 52:1003-1012.
3. Adiels M, Olofsson SO, Taskinen MR, Borén J. Diabetic dyslipidaemia. Curr Opin Lipidol 2006; 17:238-246.
4. von Eckardstein A, Schulte H, Assmann G. Risk for diabetes mellitus in middle-aged Caucasian male participants of the PROCAM study: implications for the definition of impaired fasting glucose by the American Diabetes Association. Prospective Cardiovascular Mü nster. J Clin Endocrinol Metab 2000; 85:3101-3108.
5. Kendall DM. The dyslipidemia of diabetes mellitus: giving triglycerides and high-density lipoprotein cholesterol a higher priority? Endocrinol Metab Clin North Am 2005; 34:27-48.
6. Tenenbaum A, Motro M, Fisman EZ, et al. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 2004; 109:2197-2202.
7. Scanu AM, Edelstein C. HDL: bridging past and present with a look at the future. FASEB J 2008; 22:4044-4054.
8. Kontush A, Chapman MJ. Why is HDL functionally deficient in type 2 diabetes? Curr Diab Rep 2008; 8:51-59.
9. Brites FD, Cavallero E, de Geitere C, et al. Abnormal capacity to induce cholesterol efflux and a new LpA-I prebeta particle in type 2 diabetic patients. Clin Chim Acta 1999; 279:1-14.
10. Syvänne M, Castro G, Dengremont C, et al. Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and noninsulin-dependent diabetes: importance of LpA-I:A-II particles and phospholipid transfer protein. Atherosclerosis 1996; 127:245-253.
11. Nobécourt E, Jacqueminet S, Hansel B, et al. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia2005; 48:529-538.
12. de Souza JA, Vindis C, Hansel B, et al. Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity. Atherosclerosis 2008; 197:84-94.
13. Feingold KR, Grunfeld C, Pang M, et al. LDL subclass phenotypes and triglyceride metabolism in noninsulin-dependent diabetes. Arterioscler Thromb 1992; 12:1496-1502.
14. Verges B. Lipid modification in type 2 diabetes: the role of LDL and HDL. Fundam Clin Pharmacol 2009; 23:681-685.
15. Galland F, Duvillard L, Petit JM, et al. Effect of insulin treatment on plasma oxidized LDL/LDL-cholesterol ratio in type 2 diabetic patients. Diabetes Metab 2006; 32:625-631.
16. Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1992; 93:189-199.
17. Cominacini L, Garbin U, PastorinoAM, et al. Increased susceptibility of LDL to in vitro oxidation in patients with insulin-dependent and noninsulin-dependent diabetes mellitus. Diabetes Res 1994; 26:173-184.
18. Rütti S, Ehses JA, Sibler RA, et al. Low and high-density lipoproteins modulate function, apoptosis and proliferation of primary human and murine pancreatic beta cells. Endocrinology 2009; 150:4521-4530.
19. Drew BG, Duffy SJ, Formosa MF, et al. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 2009; 119:2103-2111.
20. Abderrahmani A, Niederhauser G, Favre D, et al. Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells. Diabeto-logia 2007; 50:1304-1314.
21. Yvan-Charvet L, Wang N, Tall A. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol 2009; 29:1-5.
22. Brunham LR, Kruit JK, Pape TD, et al. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 2007; 13:340-347.
23. Villarreal-Molina MT, Aguilar-Salinas CA, Rodŕguez-Cruz M, et al. The ATP-binding cassette transporter A1 R230C variant affects HDL cholesterol levels and BMI in the Mexican population: association with obesity and obesity-related comorbidities. Diabetes 2007; 56:1881-1887.
24. Vergeer M, Brunham LR, Koetsveld J, et al. Carriers of loss-of-function mutations in ABCA1 display pancreatic beta cell dysfunction. Diabetes Care 2010; 33:869-874.
25. Hao M, Head WS, Gunawardana SC, et al. Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction. Diabetes 2007; 56:2328-2338.
26. Di Paolo G, De Camilli P. Phosphoinositides in cell regulation and membrane dynamics. Nature 2006; 443:651-657.
27. Thore S, Wuttke A, Tengholm A. Rapid turnover of phosphatidylinositol-4, 5-bisphosphate in insulin-secreting cells mediated by Ca2+ and the ATP-to-ADP ratio. Diabetes 2007; 56:818-826.
28. Hao M, Bogan JS. Cholesterol regulates glucose-stimulated insulin secretion through phosphatidylinositol 4,5-bisphosphate. J Biol Chem 2009; 284: 29489-29498.
29. Kruit JK, Kremer PHC, Dai L, et al. Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function. Diabetologia 2010 (in press).
30. Cnop M, Grupping A, Hoorens A, et al. Endocytosis of low-density lipoprotein by human pancreatic beta cells and uptake in lipid-storing vesicles, which increase with age. Am J Pathol 2000; 156:237-244.
31. Grupping AY, Cnop M, Van Schravendijk CF, et al. Low density lipoprotein binding and uptake by human and rat islet beta cells. Endocrinology 1997; 138:4064-4068.
32. Roehrich ME, MooserV, Lenain V, et al. Insulin-secreting beta-cell dysfunction induced by human lipoproteins. J Biol Chem 2003; 278:18368-18375.
33. Pétremand J, Bulat N, Butty AC, et al. Involvement of 4E-BP1 in the protection induced by HDLs on pancreatic beta cells. Mol Endocrinol 2009; 23:1572-1586.
34. Li XA, Guo L, Dressman JL, et al. A novel ligand-independent apoptotic pathway induced by scavenger receptor class B, type I and suppressed by endothelial nitric-oxide synthase and high density lipoprotein. J Biol Chem 2005; 280:19087-19096.
35. Terasaka N, Yu S, Yvan-Charvet L, et al. ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet. J Clin Invest 2008; 118:3701-3713.
36. Nofer JR, Levkau B, Wolinska I, et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphin-golipids. J Biol Chem 2001; 276:34480-34485.
37. Kimura T, Sato K, Malchinkhuu E, et al. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler Thromb Vasc Biol 2003; 23:1283-1288.
38. Radojkovic C, Genoux A, Pons V, et al. Stimulation of cell surface F1-ATPase activity by apolipoprotein A-I inhibits endothelial cell apoptosis and promotes proliferation. Arterioscler Thromb Vasc Biol 2009; 29:1125-1130.
39. Gerin I, Dolinsky VW, Shackman JG, et al. LXRbeta is required for adipocyte growth, glucose homeostasis, and beta cell function. J Biol Chem 2005; 280:23024-32331
40. Laychock SG, Tian Y, Sessanna SM. Endothelial differentiation gene receptors in pancreatic islets and INS-1 cells. Diabetes 2003; 52:1986-1993.
41. Størling J, Binzer J, Andersson AK, et al. Nitric oxide contributes to cytokine-induced apoptosis in pancreatic beta cells via potentiation of JNK activity and inhibition of Akt. Diabetologia 2005; 48:2039-2050.
42. Tang C, Vaughan AM, Oram JF. Janus kinase 2 modulates the apolipoprotein interactions with ABCA1 required for removing cellular cholesterol. J Biol Chem 2004; 279:7622-7628.
43. Tang C, Liu Y, KesslerPS, et al.The macrophagecholesterol exporter ABCA1 functions as an anti-inflammatory receptor. J Biol Chem 2009; 284:32336-32343.
44. Rezende LF, Vieira AS, Negro A, et al. Ciliary neurotrophic factor (CNTF) signals through STAT3-SOCS3 pathway and protects rat pancreatic islets from cytokine-induced apoptosis. Cytokine 2009; 46:65-71.
45. Cnop M, Hannaert JC, Grupping AY, Pipeleers DG. Low density lipoprotein can cause death of islet beta-cells by its cellular uptake and oxidative modification. Endocrinology 2002; 143:3449-3453.
46. Donath MY, Böni-Schnetzler M, Ellingsgaard H, Ehses JA. Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. Physiology (Bethesda) 2009; 24:325-331.
47. Böni-Schnetzler M,ThorneJ, Parnaud G, et al. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta-cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and auto-stimulation. J Clin Endocrinol Metab 2008; 93:4065-4074.
48. Ehses JA, Perren A, Eppler E, et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 2007; 56:2356-2370.
49. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356:1517-1526.
50. Ehses JA, Lacraz G, Giroix MH, et al. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. ProcNatl Acad Sci USA 2009; 106:13998-14003.
51. Sauter NS, Schulthess FT, Galasso R, et al. The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia. Endocrinology 2008; 149:2208-2218.
52. Boni-Schnetzler M, Boller S, Debray S, et al. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 2009; 150:5218-5229.
53. ParkerTS, Levine DM, Chang JC, et al. Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole blood. Infect Immun 1995; 63:253-258.
54. Flegel WA, Baumstark MW, Weinstock C, et al. Prevention of endotoxin-induced monokine release by human low-and high-density lipoproteins and by apolipoprotein A-I. Infect Immun 1993; 61:5140-5146.
55. Hoang A, Murphy AJ, Coughlan MT, et al. Advanced glycation of apolipoprotein A-I impairs its antiatherogenic properties. Diabetologia 2007; 50:1770-1779.
56. Passarelli M, Tang C, McDonald TO, et al. Advanced glycation end product precursors impair ABCA1-dependent cholesterol removal from cells. Diabetes 2005; 54:2198-2205.
57. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56:1761-1772.
58. Yvan-Charvet L, Ranalletta M, Wang N, et al. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest 2007; 117:1-9.
59. Out R, Jessup W, Le Goff W, et al. Coexistence of foam cells and hypocho-lesterolemia in mice lacking the ABC transporters A1 and G1.Circ Res 2008; 102:113-120.
60. Baldán A, Gomes AV, Ping P, Edwards PA. Loss of ABCG1 results in chronic pulmonary inflammation. J Immunol 2008; 180:3560-3568.
61. Francone OL, Royer L, Boucher G, et al. Increased cholesterol deposition, expression of scavenger receptors, and response to chemotactic factors in Abca1-deficient macrophages. Arterioscler Thromb Vasc Biol 2005; 25: 1198-1205.
62. Koseki M, Hirano K, Masuda D, et al. Increased lipid rafts and accelerated lipopolysaccharide-induced tumor necrosis factor-alpha secretion in Abca1-deficient macrophages. J Lipid Res 2007; 48:299-306.
63. Yvan-Charvet L, Welch C, Pagler TA, et al. Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation 2008; 118:1837-1 847.
64. Zhu X, Lee JY, Timmins JM, et al. Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages. J Biol Chem 2008; 283:22930-22941.
65. Patel S, Drew BG, Nakhla S, et al. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J Am Coll Cardiol 2009; 53:962-971.